Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry
Lung · 2024
DOI: 10.1007/s00408-024-00694-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung, 2024. Verfasst von Sarah E Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Disease Progression, Biomarkers, Registries, Lung Diseases, Interstitial. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech.
Abstract (Originalsprache)
Introduction
Pulmonary fibrosis is a characteristic of various interstitial lung diseases (ILDs) with differing etiologies. Clinical trials in progressive pulmonary fibrosis (PPF) enroll patients based on previously described clinical criteria for past progression, which include a clinical practice guideline for PPF classification and inclusion criteria from the INBUILD trial. In this study, we compared the ability of past FVC (forced vital capacity) progression and baseline biomarker levels to predict future progression in a cohort of patients from the PFF Patient Registry.
Methods
Biomarkers previously associated with pathobiology and/or progression in pulmonary fibrosis were selected to reflect cellular senescence (telomere length), pulmonary epithelium (SP-D, RAGE), myeloid activation (CXCL13, YKL40, CCL18, OPN) and fibroblast activation (POSTN, COMP, PROC3).
Results
PFF or INBUILD-like clinical criteria was used to separate patients into past progressor and non-past progressor groups, and neither clinical criterion appeared to enrich for patients with greater future lung function decline. All baseline biomarkers measured were differentially expressed in patient groups compared to healthy controls. Baseline levels of SP-D and POSTN showed the highest correlations with FVC slope over one year, though correlations were low.
Conclusions
Our findings provide further evidence that prior decline in lung function may not predict future disease progression for ILD patients, and elevate the need for molecular definitions of a progressive phenotype. Across ILD subtypes, certain shared pathobiologies may be present based on the molecular profile of certain biomarker groups observed. In particular, SP-D may be a common marker of pulmonary injury and future lung function decline across ILDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genentech, Inc, South San Francisco, CA, USA.
- Department of Medicine, University of California, San Francisco, CA, USA.
- Genentech, Inc, South San Francisco, CA, USA. neighbom@gene.com.
Förderung
- Genentech
Zitieren
APA
Chang, S. E., Jia, G., Gao, X., Schiffman, C., Gupta, S., Wolters, P., & Neighbors, M. (2024). Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry. Lung. https://doi.org/10.1007/s00408-024-00694-2
Vancouver
Chang SE, Jia G, Gao X, Schiffman C, Gupta S, Wolters P, et al. Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry. Lung. 2024. doi:10.1007/s00408-024-00694-2
BibTeX
@article{Chang2024,
author = {Chang, Sarah E and Jia, Guiquan and Gao, Xia and Schiffman, Courtney and Gupta, Sachin and Wolters, Paul and Neighbors, Margaret},
title = {Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry},
journal = {Lung},
year = {2024},
doi = {10.1007/s00408-024-00694-2}
}
EUVIMED